Recombinant Human Udp-Glucuronosyltransferase 1A7 (UGT1A7) Protein (His)

Name: Recombinant Human Udp-Glucuronosyltransferase 1A7 (UGT1A7) Protein (His)
Brand: Beta LifeScience
SKU: BLC-07935P
Availability: InStock

Greater than 85% as determined by SDS-PAGE.

Collections: All products, High-quality recombinant proteins, Other recombinant proteins, Recombinant proteins fall special offers - full-length proteins, Recombinant transmembrane proteins – fall special offers

Our products are highly customizable to meet your specific needs. You can choose options such as endotoxin removal, liquid or lyophilized forms, preferred tags, and the desired functional sequence range for proteins. Submitting a written inquiry expedites the quoting process.

Submit an inquiry today to inquire about all available size options and prices! Connect with us via the live chat in the bottom corner to receive immediate assistance.

Product Overview

Description	Recombinant Human Udp-Glucuronosyltransferase 1A7 (UGT1A7) Protein (His) is produced by our E.coli expression system. This is a full length protein.
Purity	Greater than 85% as determined by SDS-PAGE.
Uniprotkb	Q9HAW7
Target Symbol	UGT1A7
Synonyms	(UGT1A7)(UDP-glucuronosyltransferase 1-7)(UDPGT 1-7)(UGT1*7)(UGT1-07)(UGT1.7)(UDP-glucuronosyltransferase 1-G)(UGT-1G)(UGT1G)
Species	Homo sapiens (Human)
Expression System	in vitro E.coli expression system
Tag	N-10His
Target Protein Sequence	GKLLVVPMDGSHWFTMQSVVEKLILRGHEVVVVMPEVSWQLGRSLNCTVKTYSTSYTLEDQDREFMVFADARWTAPLRSAFSLLTSSSNGIFDLFFSNCRSLFNDRKLVEYLKESCFDAVFLDPFDACGLIVAKYFSLPSVVFARGIFCHYLEEGAQCPAPLSYVPRLLLGFSDAMTFKERVWNHIMHLEEHLFCPYFFKNVLEIASEILQTPVTAYDLYSHTSIWLLRTDFVLEYPKPVMPNMIFIGGINCHQGKPVPMEFEAYINASGEHGIVVFSLGSMVSEIPEKKAMAIADALGKIPQTVLWRYTGTRPSNLANNTILVKWLPQNDLLGHPMTRAFITHAGSHGVYESICNGVPMVMMPLFGDQMDNAKRMETKGAGVTLNVLEMTSEDLENALKAVINDKSYKENIMRLSSLHKDRPVEPLDLAVFWVEFVMRHKGAPHLRPAAHDLTWYQYHSLDVIGFLLAVVLTVAFITFKCCAYGYRKCLGKKGRVKKAHKSKTH
Expression Range	26-530aa
Protein Length	Full Length of Mature Protein
Mol. Weight	60.0 kDa
Research Area	Metabolism
Form	Liquid or Lyophilized powder
Buffer	Liquid form: default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution	Briefly centrifuged the vial prior to opening to bring the contents to the bottom. Reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL. It is recommended to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. The default final concentration of glycerol is 50%.
Storage	1. Store at -20°C/-80°C upon receipt, aliquoting is necessary for mutiple use. 2. Avoid repeated freeze-thaw cycles. 3. Store working aliquots at 4°C for up to one week. 4. In general, protein in liquid form is stable for up to 6 months at -20°C/-80°C. Protein in lyophilized powder form is stable for up to 12 months at -20°C/-80°C.
Notes	Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.

Target Details

Target Function	UDP-glucuronosyltransferase (UGT) that catalyzes phase II biotransformation reactions in which lipophilic substrates are conjugated with glucuronic acid to increase the metabolite's water solubility, thereby facilitating excretion into either the urine or bile. Essential for the elimination and detoxification of drugs, xenobiotics and endogenous compounds. Catalyzes the glucuronidation of endogenous estrogen hormone epiestradiol. Also catalyzes the glucuronidation of the isoflavones genistein, daidzein, glycitein, formononetin, biochanin A and prunetin, which are phytoestrogens with anticancer and cardiovascular properties. Involved in the glucuronidation of the AGTR1 angiotensin receptor antagonist caderastan, a drug which can inhibit the effect of angiotensin II. Involved in the biotransformation of 7-ethyl-10-hydroxycamptothecin (SN-38), the pharmacologically active metabolite of the anticancer drug irinotecan. Also metabolizes mycophenolate, an immunosuppressive agent.; Lacks UGT glucuronidation activity but acts as a negative regulator of isoform 1.
Subcellular Location	Endoplasmic reticulum membrane; Single-pass membrane protein.
Protein Families	UDP-glycosyltransferase family
Database References	HGNC: 12539 OMIM: 191740 KEGG: hsa:54577 STRING: 9606.ENSP00000362525 UniGene: PMID: 25899702 Increased UGT1A7 expression is associated with pancreatic cancer. PMID: 25743847 The rate of Results show that UGT1A712 allele frequency was not significantly different between the Uzbek and Japanese populations. PMID: 24453052 The presence of UGT1A128, UGT1A73, UGT1A922 genotypes decreases SN-38 clearance between 20 and 36% PMID: 23789755 Results suggest that CYP3A4 changes the catalytic function of the UGT1A subfamily in a UGT isoform-specific manner. PMID: 24255116 Polymorphism in UDP-glucuronosyltransferase 1A7 is associated with colorectal cancer. PMID: 22901212 the UGT1A73 allele is a risk factor for cancer among Asians, especially for hepatocellular carcinoma (Meta-Analysis) PMID: 22402308 there is a cancer risk associated with UGT1A73, Intermediate, and Low activity UGT1A7 genotypes, which is most evident in Asian individuals. PMID: 22085268 UGT1A7 variants play a relevant role for pancreas diseases PMID: 21440586 7-fold increased risk of cancer was observed in smokers with UGT1A7 low activity genotypes. UGT1A7 haplotype carrying C allele (T622C) showed 10-fold increased risk of cancer. PMID: 20534012 UGT1A7 heterozygosity predicted lower mycophenolic acid (MPA) trough concentrations. PMID: 20567810 In a study of Japanese renal transplant recipients, there are no significant differences in the area under the plasma concentration-time curve ratio of mycophenolic acid (MPA) glucuronide/MPA between UGT1A7 I399C/T genotypes. PMID: 18695635 The genetic polymorphisms of UGT1A7 are associated with the susceptibility of bladder cancer and have interactions with smoking in bladder carcinogenesis. PMID: 20193274 Data identified nine different genotypes in UGT1A7, demonstrating a high variability of alleles and haplotypes, which have important roles in modifying expression and activity of UGTs. PMID: 19712005 Frequent haplotypes containing several UGT1 allelic variants should be taken into account in studies on the association between diseases, abnormal drug reactions, and UGT1 family polymorphisms. PMID: 12732365 UGT1A7 polymorphisms together with IL-1 beta have a role in hepatocellular carcinoma in Japanese Hepatitic C virus-infected patients PMID: 15073122 Genetic polymorphisms in UGT1A7 is associated with colorectal cancer PMID: 15319294 the allele frequencies of UGT1A7 gene in Taiwan Chinese are different from those in Caucasians and Japanese PMID: 15682470 carriage of the UGT1A73 allele, as well as variant-211 UGT1A1 allele represents a risk factor for the development of, and a determinant for, metastases associated with colorectal cancer patients PMID: 15929176 UDP-glucuronosyltransferase 1A7 genetic polymorphisms are associated with hepatocellular carcinoma risk and onset age. PMID: 16086712 UGT1A7 polymorphisms do not predispose patients to the development of pancreatic cancer and pancreatitis PMID: 16199544 UGT1A7 polymorphisms may have a significant modifying effect on colorectal cancer risk. PMID: 16724991 analysis of the linkage disequilibrium of UGT1A1 6 and UGT1A1 28 in relation to UGT1A6 and UGT1A7 polymorphisms PMID: 16969497 most of the previously reported genetic associations between UGT1A7 and gastrointestinal cancers are based on primer-dependent genotyping errors PMID: 17325733 Genetic linkage of UGT1A7 and UGT1A9 polymorphisms to UGT1A16, related to reduced catalytic and transcriptional activities of UGTs, is associated with the decreased glucuronosyltransferase activity for SN-38 in Japanese PMID: 17406868 UGT1A1 and UGT1A7 variant alleles are associated with increased risk of Gilbert's syndrome in Taiwanese adults PMID: 17850628 Our study shows that UGT1A7 may play a role in hepatocellular carcinogenesis and that this role may differ according to the primary cause of the cirrhosis. PMID: 18021430 This study demonstrates the novel findings that carriage of low-activity UGT1A7 genotypes represents a risk factor for the development and functional severity of liver cirrhosis. PMID: 18054330 the UGT1A7 haplotype is a suitable susceptibility marker for the development of hepatocellular carcinoma in hepatitis B carriers. PMID: 18271934 Irenotecan toxicity is more likely in patients with Gilbert's syndrome carrying the UGT1A128 allele combined with reduced function UGT1A7 N129K/R131K and UGT1A7-57T/G SNP. PMID: 18349289 Predicted high activity UGT1A7 polymorphisms were significantly associated with an increased risk of head and neck cancer. PMID: 19360737 UGT1A variants additional to UGT1A128 might improve the prediction of the outcome of colorectal cancer patients treated with FOLFIRI. PMID: 19364970 Polymorphisms of UGT1A7 gene may alter the severity of PAH-induced chromosomal damage among the exposed workers. PMID: 19430315 Uncategorized study of gene-disease association, gene-environment interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) PMID: 19956635 Observational study of gene-disease association, gene-gene interaction, and pharmacogenomic / toxicogenomic. (HuGE Navigator) PMID: 18349289 Observational study of genotype prevalence and genetic testing. (HuGE Navigator) PMID: 15682470 Observational study of gene-environment interaction and pharmacogenomic / toxicogenomic. (HuGE Navigator) PMID: 15709193

FAQs

Please fill out the Online Inquiry form located on the product page. Key product information has been pre-populated. You may also email your questions and inquiry requests to sales1@betalifesci.com. We will do our best to get back to you within 4 business hours.

Feel free to use the Chat function to initiate a live chat. Our customer representative can provide you with a quote immediately.

Proteins are sensitive to heat, and freeze-drying can preserve the activity of the majority of proteins. It improves protein stability, extends storage time, and reduces shipping costs. However, freeze-drying can also lead to the loss of the active portion of the protein and cause aggregation and denaturation issues. Nonetheless, these adverse effects can be minimized by incorporating protective agents such as stabilizers, additives, and excipients, and by carefully controlling various lyophilization conditions.

Commonly used protectant include saccharides, polyols, polymers, surfactants, some proteins and amino acids etc. We usually add 8% (mass ratio by volume) of trehalose and mannitol as lyoprotectant. Trehalose can significantly prevent the alter of the protein secondary structure, the extension and aggregation of proteins during freeze-drying process; mannitol is also a universal applied protectant and fillers, which can reduce the aggregation of certain proteins after lyophilization.

Our protein products do not contain carrier protein or other additives (such as bovine serum albumin (BSA), human serum albumin (HSA) and sucrose, etc., and when lyophilized with the solution with the lowest salt content, they often cannot form A white grid structure, but a small amount of protein is deposited in the tube during the freeze-drying process, forming a thin or invisible transparent protein layer.

Reminder: Before opening the tube cap, we recommend that you quickly centrifuge for 20-30 seconds in a small centrifuge, so that the protein attached to the tube cap or the tube wall can be aggregated at the bottom of the tube. Our quality control procedures ensure that each tube contains the correct amount of protein, and although sometimes you can't see the protein powder, the amount of protein in the tube is still very precise.

To learn more about how to properly dissolve the lyophilized recombinant protein, please visit Lyophilization FAQs.